Читать книгу Handbuch ADHS - Группа авторов - Страница 62

Alexander GE, DeLong MR et al. (1986). Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci 9: 357–81.

Asghari V, Sanyal S et al. (1995). Modulation of intracellular cyclic AMP levels by different human dopamine D4 receptor variants. J Neurochem 65(3): 1157–65.

Asherson P, Brookes K et al. (2007). Confirmation that a specific haplotype of the dopamine transporter gene is associated with combined-type ADHD. Am J Psychiatry 164(4): 674–7.

Bhagavan HN, Coleman M et al. (1975). The effect of pyridoxine hydrochloride on blood serotonin and pyridoxal phosphate contents in hyperactive children. Pediatrics 55(3): 437–41.

Biederman J, Faraone SV (2002). Current concepts on the neurobiology of Attention-Deficit/Hyperactivity Disorder. J Atten Disord 6 (Suppl. 1): 7–16.

Bobb AJ, Castellanos FX et al. (2005). Molecular genetic studies of ADHD: 1991 to 2004. Am J Med Genet B Neuropsychiatr Genet 132B(1): 109–25.

Bonvinci C, Faraone SV, Scassellati C (2016). Attention-deficit hyperactivity disorder in adults: a systematic review and metaanalysis of genetic, pharmacogenetics and biochemical studies. Mol Psychiatry 21: 872–884.

Bowden CL, Deutsch CK et al. (1988). Plasma dopamine-beta-hydroxylase and platelet monoamine oxidase in attention deficit disorder and conduct disorder. J Am Acad Child Adolesc Psychiatry 27(2): 171–4.

Brennan AR, Arnsten AF (2008). Neuronal mechanisms underlying attention deficit hyperactivity disorder: the influence of arousal on prefrontal cortical function. Ann N Y Acad Sci 1129: 236–45.

Brookes K, Xu X et al. (2006). The analysis of 51 genes in DSM-IV combined type attention deficit hyperactivity disorder: association signals in DRD4, DAT1 and 16 other genes. Mol Psychiatry 11(10): 934–53.

Brookes KJ, J Mill et al. (2006). A common haplotype of the dopamine transporter gene associated with attention-deficit/hyperactivity disorder and interacting with maternal use of alcohol during pregnancy. Arch Gen Psychiatry 63(1): 74–81.

Caspi A, Sugden K et al. (2003). Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 301(5631): 386–9.

Castellanos FX, Elia J et al. (1994). Cerebrospinal fluid monoamine metabolites in boys with attention-deficit hyperactivity disorder. Psychiatry Res 52(3): 305–16.

Castellanos FX, Elia J et al. (1996). Cerebrospinal fluid homovanillic acid predicts behavioral response to stimulants in 45 boys with attention deficit/hyperactivity disorder. Neuropsychopharmacology 14(2): 125–37.

Cheon KA, Ryu YH et al. (2003). Dopamine transporter density in the basal ganglia assessed with [123I]IPT SPET in children with attention deficit hyperactivity disorder. Eur J Nucl Med Mol Imaging 30(2): 306–11.

Cheon KA, Ryu YH et al. (2005). The homozygosity for 10-repeat allele at dopamine transporter gene and dopamine transporter density in Korean children with attention deficit hyperactivity disorder: relating to treatment response to methylphenidate. Eur Neuropsychopharmacol 15(1): 95–101.

Coleman M (1971). Serotonin concentrations in whole blood of hyperactive children. J Pediatr 78(6): 985–90.

Cook EH Jr., Stein MA et al. (1995). Association of attention-deficit disorder and the dopamine transporter gene. Am J Hum Genet 56(4): 993–8.

Cragg SJ, Hille CJ et al. (2002). Functional domains in dorsal striatum of the nonhuman primate are defined by the dynamic behavior of dopamine. J Neurosci 22(13): 5705–12.

Dougherty DD, Bonab AA et al. (1999). Dopamine transporter density in patients with attention deficit hyperactivity disorder. Lancet 354(9196): 2132–3.

Endres D, Perloy E, Maier S, Feige B, Nickel K, Goll P, Bubl E, Lange t, Glauche V, Graf E, Ebert D, Sobanski E, Philipsen A, Tebartz van Elst L (2015). Normal neurochemistry in the prefontal and cerebellar brain of adults with attention-deficit hyperactivity disorder. Front Behav Neurosci 9: 242.

Endres D, Tebartz van Elst L, Maier SJ, Feige B, Goll P, Meyer SA, Matthies S, Domschke K, Lange T, Sobanski E, Philipsen A, Nickel K, Perlov E (2019). Neurochemical sex differences in adult ADHD patients: an MRS study. Biol Sex Differ 10 (1): 50.

Ernst M, Zametkin AJ et al. (1998). DOPA decarboxylase activity in attention deficit hyperactivity disorder adults. A [fluorine-18]fluorodopa positron emission tomographic study. J Neurosci 18(15): 5901–7.

Ernst M, Zametkin AJ et al. (1999). High midbrain [18F]DOPA accumulation in children with attention deficit hyperactivity disorder. Am J Psychiatry 156(8): 1209–15.

Faraone SV, Perlis RH et al. (2005). Molecular genetics of attention-deficit/hyperactivity disorder. Biol Psychiatry 57(11): 1313–23.

Frank MJ, Claus ED (2006). Anatomy of a decision: striato-orbitofrontal interactions in reinforcement learning, decision making, and reversal. Psychol Rev 113(2): 300–26.

Frank MJ, Woroch BS et al. (2005). Error-related negativity predicts reinforcement learning and conflict biases. Neuron 47(4): 495–501.

Gainetdinov RR, Jones SR et al. (1999a). Functional hyperdopaminergia in dopamine transporter knock-out mice. Biol Psychiatry 46(3): 303–11.

Gainetdinov RR, Wetsel WC et al. (1999b). Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity. Science 283(5400): 397–401.

Grace AA (2001). Psychostimulant actions on dopamine and limbic system function: relevance to the pathophysiology and treatment of ADHD. In: Solanto MV, Arnsten AF (Hrsg.). Stimulant Drugs and ADHD: Basic and Clinical Neuroscience. New York: Oxford University Press. S. 134–155.

Hammerness P, Biederman J, Petty C, Henin A, Moore CM (2012). Brain biochemical effects of methylphenidate treatment using proton magnetic spectroscopy in youth with attention-deficit hyperactivity disorder: a controlled pilot study. CNS Neurosci Ther 18: 34–40.

Hesse S, Ballaschkle O et al. (2006). The striatal dopamine transporter availability is reduced in adults with attention-deficit/hyperactivity disorder. J Nucl Med 47: 142P.

Ilgin N, Senol S et al. (2001). Is increased D2 receptor availability associated with response to stimulant medication in ADHD. Dev Med Child Neurol 43(11): 755–60.

Irwin M, Belendiuk K et al. (1981). Tryptophan metabolism in children with attentional deficit disorder. Am J Psychiatry 138(8): 1082–5.

Jacobs BL, Fornal CA (1995). Serotonin and behavior: a general hypothesis. In: Bloom FE, Kupfer DJ (Eds). Psychopharmacology: The Fourth Generation of Progress. New York: Lippincott Williams & Wilkins. S. 461–469.

Jucaite A, Fernell E et al. (2005). Reduced midbrain dopamine transporter binding in male adolescents with attention-deficit/hyperactivity disorder: association between striatal dopamine markers and motor hyperactivity. Biol Psychiatry 57(3): 229–38.

Kirley A, Lowe N et al. (2003). Association of the 480 bp DAT1 allele with methylphenidate response in a sample of Irish children with ADHD. Am J Med Genet B Neuropsychiatr Genet 121B(1): 50–4.

Krause J (2008). SPECT and PET of the dopamine transporter in attention-deficit/hyperactivity disorder. Expert Rev Neurother 8(4): 611–25.

Krause KH, Dresel SH et al. (2000). Increased striatal dopamine transporter in adult patients with attention deficit hyperactivity disorder: effects of methylphenidate as measured by single photon emission computed tomography. Neurosci Lett 285(2): 107–10.

Kusaga A, Yamashita Y et al. (2002). Increased urine phenylethylamine after methylphenidate treatment in children with ADHD. Ann Neurol 52(3): 372–4.

Laucht M, Skowronek M et al. (2007). Interacting effects of the dopamine transporter gene and psychosocial adversity on attention-deficit/hyperactivity disorder symptoms among 15-year-olds from a high-risk community sample. Arch Gen Psychiatry 64(5): 585–90.

Leo D, Sorrentino E et al. (2003). Altered midbrain dopaminergic neurotransmission during development in an animal model of ADHD. Neurosci Biobehav Rev 27(7): 661–9.

Leonard BE, McCartan D et al. (2004). Methylphenidate: a review of its neuropharmacological, neuropsychological and adverse clinical effects. Hum Psychopharmacol 19(3): 151–80.

Li D, Sham PC et al. (2006). Meta-analysis shows significant association between dopamine system genes and attention deficit hyperactivity disorder (ADHD). Hum Mol Genet 15(14): 2276–84.

Li J, Wang Y et al. (2007). Association between polymorphisms in serotonin transporter gene and attention deficit hyperactivity disorder in Chinese Han subjects. Am J Med Genet B Neuropsychiatr Genet 144B(1): 14–9.

Lucki I (1998). The spectrum of behaviors influenced by serotonin. Biol Psychiatry 44(3): 151–62.

Madras BK, Miller GM et al. (2005). The dopamine transporter and attention-deficit/hyperactivity disorder. Biol Psychiatry 57(11): 1397–409.

Malmberg K, Wargelius HL et al. (2008). ADHD and Disruptive Behavior scores – associations with MAO-A and 5-HTT genes and with platelet MAO-B activity in adolescents. BMC Psychiatry 8: 28.

Manzke T, Guenther U, Ponimaskin EG, Haller M, Dutschmann M, Schwarzacher S, Richter DW (2003). 5-HT4(a) receptors avert opioid-induced breathing depression without loss of analgesia. Science 301: 226–229.

Martin KF, Webb AR et al. (1987). The behavioural response to the 5-hydroxytryptamine1B (5HT1B) receptor agonist–RU-24969 may exhibit a circadian variation in the mouse. Chronobiol Int 4(4): 493–8.

Mazei MS, Pluto CP et al. (2002). Effects of catecholamine uptake blockers in the caudate-putamen and subregions of the medial prefrontal cortex of the rat. Brain Res 936(1–2): 58–67.

Mick E, Faraone SV (2008). Genetics of attention deficit hyperactivity disorder. Child Adolesc Psychiatr Clin N Am 17(2): 261–84, vii–viii.

Mill J, Sagvolden T et al. (2005). Sequence analysis of Drd2, Drd4, and Dat1 in SHR and WKY rat strains. Behav Brain Funct 1: 24.

Naaijen J, Forde NJ, Lythgoe DJ, Akkermans SE, Openeer TJ, Dietrich A, Zwiers MP, Hoekstra PJ, Buitelaar JK (2016). Fronto-striatal glutamate in children with Tourette`s disorder and attention-deficit/hyperactivity disorder. Neuroimage Clin 13: 16–23.

Neuman RJ, Lobos E et al. (2007). Prenatal smoking exposure and dopaminergic genotypes interact to cause a severe ADHD subtype. Biol Psychiatry 61(12): 1320–8.

O’Reilly RC, Frank MJ (2006). Making working memory work: a computational model of learning in the prefrontal cortex and basal ganglia. Neural Comput 18(2): 283–328.

Oades RD (2002). Dopamine may be ›hyper‹ with respect to noradrenaline metabolism, but ›hypo‹ with respect to serotonin metabolism in children with attention-deficit hyperactivity disorder. Behav Brain Res 130(1–2): 97–102.

Oades RD (2005). The Roles of Norepinephrine and Serotonin in Attenion Deficit Hyperactivity Disorder. In: Gozal D, Molfese DL (Eds.). Attention Deficit Hyperactivity Disorder: From Genes to Patients. Totowa, NJ: Humana Press. S. 97–130.

Oades RD (2006). Function and dysfunction of monamine interactions in children and adolescents with AD/HD. In: Levin ED (Ed.). Neurotransmitter Interactions and Cognitive Function. Basel: Birkhäuser. S. 207–244.

Oades RD (2007). Role of the serotonin system in ADHD: treatment implications. Expert Rev Neurother 7(10): 1357–74.

Oades RD, Muller B (1997). The development of conditioned blocking and monoamine metabolism in children with attention-deficit-hyperactivity disorder or complex tics and healthy controls: an exploratory analysis. Behav Brain Res 88(1): 95–102.

Oades RD, Daniels R et al. (1998). Plasma neuropeptide-Y levels, monoamine metabolism, electrolyte excretion and drinking behavior in children with attention-deficit hyperactivity disorder. Psychiatry Res 80(2): 177–86.

Ogdie MN, Bakker SC et al. (2006). Pooled genome-wide linkage data on 424 ADHD ASPs suggests genetic heterogeneity and a common risk locus at 5p13. Mol Psychiatry 11(1): 5–8.

Palsson E, Sellgren C, Rydén E, Kizza R, Pelanis A, Zetterberg H, Blennow K, Landén Mikael (2017). Cerebrospinal fluid monoamine metabolite profiles in bipolar disorder, ADHD and controls. J Neural Transm 124: 1135–1143.

Pliszka SR (2005). The neuropsychopharmacology of attention-deficit/hyperactivity disorder. Biol Psychiatry 57(11): 1385–90.

Prince J (2008). Catecholamine Dysfunction in Attention-Deficit/Hyperactivity Disorder. J Clin Psychopharmacol 28 (Suppl. 2): 39–45.

Rajkowski J, Majczynski H, Clayton E, Aston-Jones GS (2004). Activation of monkey locus coeruleus neurons varies with difficulty and performance in a target detection task. J Neurophysiol 92: 361–371.

Rapoport J, Quinn P et al. (1974). Platelet serotonin of hyperactive school age boys. Br J Psychiatry 125(2): 138–40.

Reimherr FW, Wender PH et al. (1984). Cerebrospinal fluid homovanillic acid and 5-hydroxy-indoleacetic acid in adults with attention deficit disorder, residual type. Psychiatry Res 11(1): 71–8.

Retz W, Freitag CM et al. (2008). A functional serotonin transporter promoter gene polymorphism increases ADHD symptoms in delinquents: interaction with adverse childhood environment. Psychiatry Res 158(2): 123–31.

Riikonen RS, Nokelainen P et al. (2005). Deep serotonergic and dopaminergic structures in fetal alcoholic syndrome: a study with nor-beta-CIT-single-photon emission computed tomography and magnetic resonance imaging volumetry. Biol Psychiatry 57(12): 1565–72.

Roessner V, Walitza S et al. (2007). Tetrahydroisoquinoline derivatives: a new perspective on monoaminergic dysfunction in children with ADHD? Behav Brain Funct 3(1): 64.

Roessner V, Manzke T et al. (2009a). Development of 5-HT transporter density and long-term effects of methylphenidate in an animal model of ADHD. World J Biol Psychiatry 26(1):1–5.

Roessner V, Sagvolden T et al. (2009a). MPH treatment normalizes elevated dopamine transporter density in an animal model of ADHD (submitted).

Ruskin DN, Bergstrom DA et al. (2001). Drugs used in the treatment of attention-deficit/hyperactivity disorder affect postsynaptic firing rate and oscillation without preferential dopamine autoreceptor action. Biol Psychiatry 49(4): 340–50.

Russell VA (2002). Hypodopaminergic and hypernoradrenergic activity in prefrontal cortex slices of an animal model for attention-deficit hyperactivity disorder– the spontaneously hypertensive rat. Behav Brain Res 130(1–2): 191–6.

Russell VA, Sagvolden T et al. (2005). Animal models of attention-deficit hyperactivity disorder. Behav Brain Funct 1: 9.

Sagvolden T, Johansen EB et al. (2005). A dynamic developmental theory of attention-deficit/hyperactivity disorder (ADHD) predominantly hyperactive/impulsive and combined subtypes. Behav Brain Sci 28(3): 397–419; discussion 419–68.

Schiffer WK, Volkow ND et al. (2006). Therapeutic doses of amphetamine or methylphenidate differentially increase synaptic and extracellular dopamine. Synapse 59(4): 243–51.

Shaw P, Sharp WS, Morrison M, Eckstrand K, Greenstein DK, Clasen LS, Evans AL, Rapoport JL (2009). Psychostimulant Treatment and the developing cortex in attention deficit hyperactivity. Am J Psychiatry 166(1): 58–63.

Shaywitz BA, Cohen DJ et al. (1977). CSF monoamine metabolites in children with minimal brain dysfunction: evidence for alteration of brain dopamine. A preliminary report. J Pediatr 90(1): 67–71.

Sheehan K, Lowe N et al. (2005). Tryptophan hydroxylase 2 (TPH2) gene variants associated with ADHD. Mol Psychiatry 10(10): 944–9.

Sheehan K, Hawi Z et al. (2007). No association between TPH2 gene polymorphisms and ADHD in a UK sample. Neurosci Lett 412(2): 105–7.

Shekim WO, Bylund DB et al. (1986). Platelet MAO and measures of attention and impulsivity in boys with attention deficit disorder and hyperactivity. Psychiatry Res 18(2): 179–88.

Shetty T, Chase TN (1976). Central monoamines and hyperkinase of childhood. Neurology 26(10): 1000–2.

Sikstrom S, Soderlund G (2007). Stimulus-dependent dopamine release in attention-deficit/hyperactivity disorder. Psychol Rev 114(4): 1047–75.

Solanto MV (2002). Dopamine dysfunction in AD/HD: integrating clinical and basic neuroscience research. Behav Brain Res 130(1–2): 65–71.

Spivak B, Vered Y et al. (1999). Circulatory levels of catecholamines, serotonin and lipids in attention deficit hyperactivity disorder. Acta Psychiatr Scand 99(4): 300–4.

Tripp G, Wickens JR (2008). Research review: dopamine transfer deficit: a neurobiological theory of altered reinforcement mechanisms in ADHD. J Child Psychol Psychiatry 49(7): 691–704.

Volkow ND, Ding YS et al. (1995). Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in the human brain. Arch Gen Psychiatry 52(6): 456–63.

Volkow ND, Wang G et al. (2001). Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. J Neurosci 21(2): RC121.

Walitza S, Renner TJ et al. (2005). Transmission disequilibrium of polymorphic variants in the tryptophan hydroxylase-2 gene in attention-deficit/hyperactivity disorder. Mol Psychiatry 10(12): 1126–32.

Watanabe Y, Fujita M et al. (1997). Brain dopamine transporter in spontaneously hypertensive rats. J Nucl Med 38(3): 470–4.

Wilens TE (2008). Effects of Methylphenidate on the Catecholaminergic Sytstem in Attention-Deficit/Hyperactivity Disorder. J Clin Psychopharmcaol 28 (Suppl. 2): S46–S53.

Williams J (2008). Working toward a neurobiological account of ADHD: commentary on Gail Tripp and Jeff Wickens, dopamine transfer deficit. J Child Psychol Psychiatry 49(7): 705–11; discussion 711.

Yano M, Steiner H (2005). Methylphenidate (Ritalin) induces Homer 1a and zif 268 expression in specific corticostriatal circuits. Neuroscience 132(3): 855–65.

Zhang K, Davids E et al. (2002). Serotonin transporter binding increases in caudate-putamen and nucleus accumbens after neonatal 6-hydroxydopamine lesions in rats: implications for motor hyperactivity. Brain Res Dev Brain Res 137(2): 135–8.

4 Noradrenalin wird international i. d. R. als Norepinephrin benannt, weswegen hier auch die Abkürzung NE benutzt wird.